Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced that it will participate in the following investor conferences:
- The Ladenburg Thalmann 2018 Healthcare Conference, on Tuesday, October 2, 2018, at 3:30 p.m. Eastern Time, at the Sofitel New York. Akebia will participate in a renal anemia-themed panel discussion; and
- The BTIG Biotech Conference on Thursday, October 25, 2018, at the Langham Hotel, New York.
A replay of the webcast from the Ladenburg Thalmann conference will be available on the company’s website at www.akebia.com the day following the conference. To access, please log onto the Akebia website at least 15 minutes prior to the webcast to ensure adequate time for any software downloads that may be required.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor biology. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180925005748/en/
Contacts:
John Garabo, 617-844-6130
Director,
Corporate Communications
jgarabo@akebia.com
